Single bolus PCSK9 Inhibition: A new approach to plaque stabilisation

被引：0
作者：
Nicholls, Stephen J. [1 ]
Manmathan, Gavin PR. [1 ]
机构：
[1] Monash Univ, Victorian Heart Inst, Clayton, Australia
来源：
ATHEROSCLEROSIS | 2024年 / 399卷
关键词：
Lipids; PCSK9; inhibitors; Imaging; Atherosclerosis; EVOLOCUMAB;
D O I：
10.1016/j.atherosclerosis.2024.118628
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [41] A review of PCSK9 inhibition and its effects beyond LDL receptors
    Dixon, Dave L.
    Trankle, Cory
    Buckley, Leo
    Parod, Eric
    Carbone, Salvatore
    Van Tassell, Benjamin W.
    Abbate, Antonio
    JOURNAL OF CLINICAL LIPIDOLOGY, 2016, 10 (05) : 1073 - 1080
  • [42] PCSK9 inhibition as an emerging lipid lowering therapy: Unanswered questions
    Rallidis, Loukianos S.
    Lekakis, John
    HELLENIC JOURNAL OF CARDIOLOGY, 2016, 57 (02) : 86 - 91
  • [43] How many familial hypercholesterolemia patients are eligible for PCSK9 inhibition?
    Masana, Luis
    Plana, Nuria
    Perez-Calahorra, Sofia
    Ibarretxe, Daiana
    Lamiquiz-Moneo, Itziar
    Pedro-Botet, Juan
    Suarez-Tembra, Manuel
    Valdivielso, Pedro
    Ortega, Emilio
    Civeira, Fernando
    ATHEROSCLEROSIS, 2017, 262 : 107 - 112
  • [44] Metabolic effects of PCSK9 inhibition with Evolocumab in subjects with elevated Lp(a)
    Zhang, Xiang
    Stiekema, Lotte C. A.
    Stroes, Erik S. G.
    Groen, Albert K.
    LIPIDS IN HEALTH AND DISEASE, 2020, 19 (01)
  • [45] PCSK9 Inhibition-Based Therapeutic Approaches: An Immunotherapy Perspective
    Momtazi-Borojeni, Amir Abbas
    Pirro, Matteo
    Xu, Suowen
    Sahebkar, Amirhossein
    CURRENT MEDICINAL CHEMISTRY, 2022, 29 (06) : 980 - 999
  • [46] Metabolic effects of PCSK9 inhibition with Evolocumab in subjects with elevated Lp(a)
    Xiang Zhang
    Lotte C. A. Stiekema
    Erik S. G. Stroes
    Albert K. Groen
    Lipids in Health and Disease, 19
  • [47] PCSK9 inhibitors in hypercholesterolemia. New hope for patients with diabetes mellitus?
    Parhofer, K. G.
    HERZ, 2016, 41 (03) : 217 - 223
  • [48] PCSK9 inhibitors: an overview on a new promising lipid-lowering therapy
    Denegri, Andrea
    Petrova-Slater, Iveta
    Pasotti, Elena
    Rossi, Maria Grazia
    Pedrazzini, Giovanni Battista
    Moccetti, Tiziano
    Moccetti, Marco
    JOURNAL OF CARDIOVASCULAR MEDICINE, 2016, 17 (04) : 237 - 244
  • [49] PCSK9 in relation to coronary plaque inflammation: Results of the ATHEROREMO-IVUS study
    Cheng, Jin M.
    Oemrawsingh, Rohit M.
    Garcia-Garcia, Hector M.
    Boersma, Eric
    van Geuns, Robert-Jan
    Serruys, Patrick W.
    Kardys, Isabella
    Akkerhuis, K. Martijn
    ATHEROSCLEROSIS, 2016, 248 : 117 - 122
  • [50] PCSK9 as a New Player in Cancer: New Opportunity or Red Herring?
    Bonaventura, Aldo
    Vecchie, Alessandra
    Ruscica, Massimiliano
    Grossi, Francesco
    Dentali, Francesco
    CURRENT MEDICINAL CHEMISTRY, 2022, 29 (06) : 960 - 969
12345